EnteroMedics

homesitemapcontact us

   search

 

   
 
 
   
   
 

Overview

 

Our Mission

 
 

Management

 
 

Board of Directors

 

NOW FDA APPROVED

Visit www.vbloc.com or call 1.800.MY.vBloc to learn more.
.
Important Safety Information for Patients >
Important Safety Information for Physicians >
Patient Manual (PDF) >

 

 

 

 

EnteroMedics® Inc. (NASDAQ: ETRM) has developed vBloc® vagal blocking therapy, a unique, broadly patented therapeutic approach to treat a range of gastrointestinal and metabolic diseases. vBloc® is a first-in-class weight loss treatment that addresses the growing global health crises associated with obesity and its co-morbidities, such as diabetes and hypertension.

vBloc® Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System controls both hunger and fullness by blocking the primary nerve which regulates the digestive system. vBloc® Therapyaddresses the lifelong challenge of obesity by empowering people to take a positive path toward weight loss without compromising their lifestyle.

The Maestro Rechargeable System supports patients in their effort to lose weight and control the co-morbidities of their obesity. We believe this innovative approach will lead more patients to take that important step toward beating obesity.

vBloc® Therapy blocks vagal nerve signaling between the brain and stomach believed to be responsible for multiple mechanisms involving metabolic control, food intake and processing, as well as sensations of hunger, satisfaction and fullness. EnteroMedics is the first company focused on treating obesity utilizing vagal blocking technology.

There is a critical and growing need for new and improved treatments for obesity, a condition with high risk for associated co-morbidities and mortality. Obesity also represents a tremendous cost burden to health care systems around the world. For this reason, EnteroMedics is pursuing a methodical, global commercialization strategy in markets where obesity is epidemic.

The Maestro Rechargeable System has received Food and Drug Adminstration (FDA) approval as well as CE Mark in Europe, and has been listed on the Australian Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA) for supply in Australia.